Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

20232,276 citationsJournal Articlegreen Open Access

Authors

A. Michael Lincoff · Cleveland Clinic Lerner College of Medicine

Kirstine Brown‐Frandsen · Cleveland Clinic Lerner College of Medicine

Helen M. Colhoun · Cleveland Clinic Lerner College of Medicine

John Deanfield · Cleveland Clinic Lerner College of Medicine

Scott S. Emerson · Cleveland Clinic Lerner College of Medicine

Sille Esbjerg · Cleveland Clinic Lerner College of Medicine

Søren Hardt‐Lindberg

Abstract

In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Pharmacology and Obesity Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 389, Issue 24, pp. 2221-2232

DOI: 10.1056/nejmoa2307563

Field-Weighted Citation Impact: 455.08